Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has accelerated approval as a second-line treatment for HER2-mutated NSCLC and is dosed ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results